Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo(Duke University), Catherine M. Bollard(Children's National), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center), Leslie Lehmann(Harvard University), Ira M. Cheifetz(Duke Children's Hospital & Health Center), Priti Tewari(The University of Texas MD Anderson Cancer Center), Jerelyn Moffet(Duke University), John M. Slopis(The University of Texas MD Anderson Cancer Center), Joan O’Hanlon Curry(The University of Texas MD Anderson Cancer Center), Agne Taraseviciute(Seattle Children's Hospital), Sajad Khazal(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Alison Gulbis(The University of Texas MD Anderson Cancer Center), Sarah Featherston(The University of Texas MD Anderson Cancer Center), Maria E. Mireles(The University of Texas MD Anderson Cancer Center), Basirat Shoberu(Albert Einstein College of Medicine), David McCall(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Hisham Abdel‐Azim(University of Southern California), Chani Traube(Memorial Sloan Kettering Cancer Center), Cathy Nguyen(The University of Texas MD Anderson Cancer Center), Jessica Foglesong(The University of Texas MD Anderson Cancer Center), Julie C. Fitzgerald(Children's Hospital of Philadelphia), Lisa Hafemeister(The University of Texas MD Anderson Cancer Center), Neena Kapoor(University of Southern California), Marie E. Steiner, Paul L. Martin(Duke University), Christine Duncan(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Jennifer McArthur(St. Jude Children's Research Hospital), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), Rajinder Bajwa(Nationwide Children's Hospital), Rodrigo Mejía(The University of Texas MD Anderson Cancer Center)
Cited by 236
Related Papers
Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children
|Pediatric Critical Care Medicine|2020|1.2k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy
|New England Journal of Medicine|2017|592